A randomized, double-blind phase 2/3 study of Fianlimab (anti-lag 3 antibody), Cemiplimab (anti-pd-1 antibody), and chemotherapy versus cemiplimab and chemotherapy in first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) irrespective of PD-L1 expression levels.

The University of Virginia is participating in a clinical research study for adults ages 18 and over, who have advanced non-small cell lung cancer (NSCLC) with any PD-L1 expression. As part of this study, you will either be treated with an investigational medication, fianlimab, a LAG-3 inhibitor, in combination with cemiplimab (a PD-1 inhibitor) or cemiplimab alone. Both medications are administered by IV.

The aim of the study is to see how effective the combination of fianlimab and cemiplimab is in treating advanced NSCLC, in comparison with cemiplimab by itself.

If you choose to be in this study, your part in the study is expected to last up to 5 years.
• Screening phase: about 28 days
• Treatment phase: up to ~2 years
• Post-treatment phase: up to ~3 years

Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT05800015

uvacancertrials@hscmail.mcc.virginia.edu